Getinge (GETI) Q3 2025 earnings summary

Executive summary

• Achieved strong organic sales growth of 9.5% in Q3 2025, with order intake up 4.7% and improved profitability and cash flow despite tariff and currency headwinds.

• Recurring revenue products now represent 65% of sales, and high-margin products account for over two-thirds of sales.

• Financial position remains robust, with leverage well below internal thresholds and solid free cash flow.

• Strategic focus on quality improvements, sustainability, and productivity, with significant reduction in field actions relative to sales.

• Acute Care Therapies and Life Science delivered double-digit organic net sales growth, driven by ventilators, ECLS therapy, cardiac surgery, and sterile transfer.

Financial highlights

• Q3 2025 organic net sales up 9.5% year-over-year to SEK 8,226M; order intake up 4.7%.

• Adjusted gross profit rose to SEK 4,051M (margin 49.2%), with adjusted EBITA at SEK 1,079M (margin 13.1%).

• Free cash flow improved to SEK 793M in Q3, supported by operating profits and working capital changes.

• Net debt at quarter-end was SEK 11.1 billion, or SEK 8.6 billion adjusted for debt liabilities; net debt/adj EBITDA at 1.4x–1.6x.

• Tariff costs totaled -SEK 108 million in Q3 and -SEK 218 million year-to-date; currency effects negatively impacted adjusted gross profit by SEK -332M and EBITA by SEK -128M.

Outlook and guidance

• 2025 organic net sales expected to grow 2–5%, with long-term financial target of over 12% EPS growth maintained despite tariff and currency headwinds.

• Priorities for 2025 include quality improvements in Acute Care Therapies, sustainability, productivity, and cost control.